The current understanding of etanercept’s failure in IBD highlights its ability to bind to soluble, but not transmembrane, TNF, which is believed to be the key source of TNF-related pathogenic effects in IBD [49]. This evidence concerns the gene TNF and inflammatory bowel disease.